Back to search
Well Differentiated Pancreatic Endocrine Tumor
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Well Differentiated Pancreatic Endocrine Tumor trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Well Differentiated Pancreatic Endocrine Tumor trials you may qualify forThe primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate pr…
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ1…
This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as…
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal…
This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the…
This study is the first randomized, open-label, national, multicenter, phase II study assessing the efficacy and safety of OCLU in subjects with pretreated prog…